DDOG vs MRK: Which Is the Better Buy?
Side-by-side comparison of Datadog, Inc. and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
Datadog, Inc. · Technology
$104.77
+55.6% upside to fair value
Grade B
High Quality
VS
Merck & Co., Inc. · Healthcare
$121.42
-2.9% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
DDOG has more upside to fair value
(+55.6%).
MRK trades at a lower forward P/E
(14.0x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DDOG |
MRK |
| Current Price |
$104.77 |
$121.42 |
| Fair Value Estimate |
$163.01 |
$118.00 |
| Upside to Fair Value |
+55.6%
|
-2.9%
|
| Market Cap |
$37.1B |
$300.2B |
| Forward P/E |
341.2x
|
14.0x
|
| EV / EBITDA |
168.3x
|
11.8x
|
| Price / Sales |
10.8x
|
4.1x
|
| Price / FCF |
37.0x
|
21.4x
|
| Revenue Growth YoY |
+7.6%
|
+1.3%
|
| Gross Margin |
79.9%
|
81.5%
|
| Operating Margin |
-1.3%
|
41.2%
|
| Return on Equity |
3.2%
|
34.7%
|
| Dividend Yield |
0% |
3.1% |
| FCF Yield |
2.7%
|
4.7%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
Datadog, Inc. is a leading cloud-based monitoring and analytics platform specializing in observability and security for cloud-native, microservices, and AI applications. The company benefits from strong product-market fit driven by extensive integrations and a customer-centric approach, reflected in 26% revenue growth to $3.43 billion in fiscal 2025 and 37.4% earnings growth year-over-year. Despi…
Merck is a top-5 global pharmaceutical company generating $65B in annual revenue with 81.5% gross margins and 28% net margins. Keytruda, the world's best-selling drug at $31.7B (49% of pharma revenue), faces patent expiry in 2028. Merck is aggressively building replacements through M&A and pipeline launches: Winrevair ($1.4B year one), Capvaxive ($759M), and the $6.7B Terns acquisition for TERN-7…
Accumulation Zones
| Metric |
DDOG |
MRK |
| Zone Low |
$122.26 |
$88.00 |
| Zone High |
$138.56 |
$100.00 |
| In Buy Zone? |
Yes
|
No
|